FibroBiologics CEO says 2026 ‘will be about execution’

FibroBiologics (FBLG) issued a letter to shareholders, which read in part, “Looking back on 2025, I’m reminded of something I’ve always believed: the best way to predict the future is to invent it. At FibroBiologics, that’s exactly what we’ve been doing by pushing the boundaries of science to create fibroblast-based therapies that may change lives. This year has been about relentless innovation and obsessing over science and long-term patient impact. Worldwide, patients are suffering from chronic diseases, and our mission is to deliver breakthroughs using fibroblast cells and fibroblast-derived materials. Let me share our progress in that spirit that’s straightforward, optimistic, and grounded in results…Looking ahead, 2026 will be about execution which includes completing a clinical trial, submitting INDs, and strengthening our financial position. We’ll continue obsessing over science, while fostering a sense of urgency for clinical validation. Challenges remain, like regulatory hurdles and funding, but our team’s grit and your support as shareholders make me confident that we will continue to conquer any challenges that stand between our science and patient relief.”